| Literature DB >> 31641661 |
Omar I Jaber1, Maxim Al Ashhab1.
Abstract
Chordoma is a rare tumor. It has unique clinical, pathological and immunohistochemical characteristics. Accurate diagnosis is essential as the tumor shows an aggressive clinical course and requires a multimodal therapeutic approach. A case with wide spread distant metastatic disease that was initially thought to represent metastatic thyroid carcinoma is presented. Appropriate clincopathologic correlation and the histologic findings raised the possibility of poorly differentiated chordoma. The diagnosis was confirmed by immunohistochemistry for INI-1 and Brachyury. The approach to the diagnosis emphasizing the clinical and pathologic findings of this case is discussed and reviewed in the context of the published literature. Autopsy and Case Reports. ISSN 2236-1960.Entities:
Keywords: Chordoma; Notochord; SMARCB1 Protein
Year: 2019 PMID: 31641661 PMCID: PMC6771453 DOI: 10.4322/acr.2019.120
Source DB: PubMed Journal: Autops Case Rep ISSN: 2236-1960
Figure 1Photomicrographs of the lung nodule. A – Poorly differentiated chordoma. The tumor is composed of sheets of epithelioid cells with eosinophilic cytoplasm (H&E, 100X); B – Poorly-differentiated chordoma. Notice the well-formed granuloma and the cells with clear cytoplasm in the lower right corner (H&E, 100X); C – Poorly-differentiated chordoma. Focal areas show tumor cells with clear to vacuolated cytoplasm admixed with epithelioid cells (H&E 200X); D – Pankeratin immunohistochemical stain highlighting the lesional cells (Pankeratin immunohistochemical stain, 100X).
Figure 2Photomicrographs of the lung nodule. A – INI-1 immunohistochemical stain in poorly differentiated chordoma. Notice the loss of expression in the tumor cells and the intact expression in the inflammatory cells (400X); B – Brachyury immunohistochemical stain in poorly differentiated chordoma (200X).
Clinical and pathologic features of the tumors included in the differential diagnosis for poorly differentiated chordoma
| Tumor | Clinical setting | Pathology |
|---|---|---|
| Carcinoma | Older patients. A primary site is often detected by imaging studies. | Variable morphology depending on the type of carcinoma and site of origin. Immunohistochemical stains often help in determining the site of origin. |
| Conventional type epithelioid sarcoma | Involves the distal extremities of young adults (median age: 30 years), involves the skin, subcutis, tendons or fascia. | Epithelioid to occasionally spindle cell proliferation with vesicular nuclei and small nucleoli, pseudogranulomatous appearance |
| Proximal type epithelioid sarcoma | Arises in the deep soft tissues of the pelvis and perineum. Older patients compared to conventional epithelioid sarcoma. | Infiltrative, multinodular sheets of epithelioid cells with prominent atypia, rhabdoid morphology and prominent nucleoli. Pseudogranulomatous appearance is not seen. |
| Epithelioid malignant peripheral nerve sheath tumor | Most often arises in the subcutaneous tissue of young to middle aged adults. Mostly in the extremities. May arise in association with a large nerve. | Well-circumscribed, multinodular growth pattern. Relatively uniform cells with abundant eosinophilic cytoplasm, vesicular nuclei and single prominent nucleolus. The stroma might be myxoid. |
| Extrarenal malignant rhabdoid tumor | Affects infants and children. Rapidly enlarging mass that involves the deep soft tissues in axial locations (neck, paraspinal areas, perineum abdominal and pelvic cavities). | Sheets of tumor cells with rhabdoid morphology with large vesicular nuclei with prominent nucleoli. Juxtanuclear eosinophilic, PAS positive-diastase resistant hyaline globules are seen. |
| Myoepithelial carcinoma | Predominates in the pediatric population. Mostly in the extremities. | The tumor shows heterogeneous morphology with epithelioid (usually the predominant pattern), clear, spindle and/or plasmacytoid cells forming nests, cords or solid sheets in a myxoid or hyalinized stroma. |
Immunohistochemical stains for the differential diagnosis of poorly differentiated chordoma
| Tumor | Keratin | S100 | INI-1 | Brachyury |
|---|---|---|---|---|
| Carcinoma | + | - | Intact | - |
| Epithelioid sarcoma | + | - | Lost | - |
| Epithelioid malignant peripheral nerve sheath tumor | + | + | Lost in 50%. | - |
| Extrarenal malignant rhabdoid tumor | + | +/- | Lost | - |
| Myoepithelial carcinoma | + | +/- | Lost in 10-40%. | - |
| Poorly differentiated chordoma | + | +/- | Lost | + |
INI-1 expression can be lost in some carcinomas including renal medullary carcinoma, a subset of myoepithelial carcinoma and rare carcinomas of the endometrium.12,13
Prognostic parameters of spinal poorly differentiated chordoma compared to spinal conventional and chondroid chordoma2
| Spinal poorly differentiated chordoma | Spinal conventional chordoma | Spinal chondroid chordoma | P value | |
|---|---|---|---|---|
| Mean overall survival | 46 months | 129 months | 101 months | 0.035 |
| Mean progression free survival | 23 months | 100 months | 60 months | <0.0005 |
| Mean local control time | 31 months | 121 months | 63 months | 0.006 |
| Mean metastasis free survival | 30 months | 165 months | 83 months | <0.005 |
When comparing spinal poorly differentiated chordoma with spinal conventional and chondroid chordoma.